drugset / Trial / NCT06938269
A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.
Timeline
- Start
- 2025-06-18
- Primary completion
- 2026-03
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MWN109 | Unknown | 4 mg | Oral |
| Comparator | MWN109 | Unknown | 7.5 mg | Oral |
| Comparator | MWN109 | Unknown | 15 mg | Oral |
| Comparator | MWN109 | Unknown | 30 mg | Oral |
| Comparator | MWN109 | Unknown | 45 mg | Oral |